Twelve cases of acneiform eruptions while on anti-CTLA4 therapy.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Macartney WelbornAnisha B Patel

Abstract

We present the first detailed report of acneiform eruptions in patients on CTLA-4 inhibitor therapy. Acneiform eruptions commonly occur (up to 75-100%) as a cutaneous adverse event associated with EGFR inhibition; however, acneiform eruptions have not been highly reported as a cutaneous adverse event associated with CTLA-4 inhibitor therapy. We conducted a retrospective chart review of our institution's database to assess cutaneous adverse events associated with ipilimumab and tremelimumab, identifying 12 patients with acneiform eruptions (2 on tremelimumab and 10 on ipilimumab). The median time to onset of rash was 3 weeks after starting CTLA-4 inhibitor therapy, ranging from 0.7-45 weeks. Median time to cutaneous resolution was 6 weeks, ranging from 2 to 282 weeks. Treatment included oral and topical antibiotics, antihistamines, and oral or topical corticosteroids with four patients receiving no treatment. Acneiform eruptions are seen less commonly with CTLA-4 inhibitors than other cancer therapies, but awareness that it does occur is important for clinical practice. Better description is a necessary help to aid in early diagnosis and intervention. While EGFR inhibitor-associated acneiform eruptions are associated with clinic...Continue Reading

References

Nov 21, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·H TomkováM Gharibyar
Aug 17, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K PotthoffA Wollenberg
Sep 14, 2011·Oncotarget·Katelyn T Byrne, Mary Jo Turk
Apr 29, 2014·Journal of the American Academy of Dermatology·Mario E LacoutureAxel Hauschild
May 20, 2017·European Journal of Dermatology : EJD·Emi DikaAnnalisa Patrizi
Aug 4, 2018·American Journal of Clinical Dermatology·Macartney WelbornAnisha B Patel

❮ Previous
Next ❯

Citations

Mar 22, 2021·Journal of the American Academy of Dermatology·Mytrang H DoMario E Lacouture

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Archives of Disease in Childhood. Education and Practice Edition
Peter A Lio, Kachiu C Lee
Cutis
J H Kuflik, R A Schwartz
The British Journal of Dermatology
F F HELLIER
Horumon to rinsho. Clinical endocrinology
E Kawagishi
American Journal of Clinical Dermatology
Priyanka VedakDaniela Kroshinsky
© 2021 Meta ULC. All rights reserved